Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

The Role of Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 1 (PDP1) in T cell-mediated Anti-tumour Immunity

FY 2016-17

Summary
CD8+ T cells are an important component of the immune system that help control disease and eliminate cancer cells in the body. However, in many cancer patients, the tumour microenvironment is immunosuppressive, which prevents CD8+ T cells from properly targeting cancer cells. Emerging forms of cancer therapy target ways to improve the patient's immune response to cancer cells, and one of these ways has been to target T cell metabolism. It has been established that activated T cells have a distinct metabolic profile which is important for their function, but many other aspects of T cell metabolism still remain poorly understood, making it challenging to develop the next generation of cancer therapies. Recent work has shown that CD8+ T cells lacking expression of the gene PDP1 , encoding pyruvate dehydrogenase phosphatase catalytic subunit 1, accumulated better in the tumour. Expression of PDP1 likely tips the balance in favour of a metabolic profile opposite of what is typically seen in activated T cells, so this evidence may suggest that inhibiting PDP1 expression can help improve anti-tumour CD8+ T cell responses. We hypothesize that PDP1 expression prevents CD8+ T cells from achieving the metabolic profile needed for full activation and proper function. We will determine the expression profile of PDP1 in CD8+ T cells, its role in T cell metabolism, and its influence on T cell anti-tumour immunity. This project will provide insight into key metabolic pathways needed to improve the immune response to cancer, which could be utilized in the development of new cancer therapies.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
367409
Name
Wong Alison
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 1 (PDP1) in T cell-mediated Anti-tumour Immunity
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunotherapy; T Cell; T Cell Metabolism; Tumour Immunology
Abstract
CD8+ T cells are an important component of the immune system that help control disease and eliminate cancer cells in the body. However, in many cancer patients, the tumour microenvironment is immunosuppressive, which prevents CD8+ T cells from properly targeting cancer cells. Emerging forms of cancer therapy target ways to improve the patient's immune response to cancer cells, and one of these ways has been to target T cell metabolism. It has been established that activated T cells have a distinct metabolic profile which is important for their function, but many other aspects of T cell metabolism still remain poorly understood, making it challenging to develop the next generation of cancer therapies. Recent work has shown that CD8+ T cells lacking expression of the gene PDP1 , encoding pyruvate dehydrogenase phosphatase catalytic subunit 1, accumulated better in the tumour. Expression of PDP1 likely tips the balance in favour of a metabolic profile opposite of what is typically seen in activated T cells, so this evidence may suggest that inhibiting PDP1 expression can help improve anti-tumour CD8+ T cell responses. We hypothesize that PDP1 expression prevents CD8+ T cells from achieving the metabolic profile needed for full activation and proper function. We will determine the expression profile of PDP1 in CD8+ T cells, its role in T cell metabolism, and its influence on T cell anti-tumour immunity. This project will provide insight into key metabolic pathways needed to improve the immune response to cancer, which could be utilized in the development of new cancer therapies.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wong, Alison
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~